MIRM - Earnings call transcript Q3 2024 | Mirum Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Hello, everyone, and welcome to the Mirum Pharmaceuticals Third Quarter 2024 Financial Results and Business Update. My name is Seb, and I'll be the operator for your call today. [Operator Instructions]. I will now hand you over to Andrew McKibben, Vice President of Investor Relations and Finance. Please go ahead.

Andrew McKibben

morning, good and Seb, everyone. Thanks, welcome I'd Quarter Mirum Third to Conference like Call. to XXXX Pharmaceuticals you I'm by Chief Chief Financial Operating Quan; joined President Eric Officer. Officer, our today and Peter our CEO, Radovich; our our Bjerkholt, Medical Joanne Peetz; Officer, Chief Chris and third Earlier the a results issued Mirum release announcing XXXX. today, company's the news for quarter of news release found section Investors the website. this and be Copies of in SEC filings our can

to we I'd start, expectations, of opportunities to judgment materially discussed. results remind be during and as for statements risks that forward-looking course from call, Mirum's including programs product our and current like today you statements results this inherently involve and represent the may medicines based conference market differ its of Before that and the will regarding candidates. management's approved certain uncertainties making These we on statements actual cause

We XX-Q Chris. for are the like to in to duty said, to that the factors our to these subsequent refer Please I'd turn and call update statements. under information. With no over latest Chris? SEC Form risk more filings

Christopher Peetz

pipeline, objectives, Andrew, have across a morning, everyone. It advancing for Mirum disease. excellent has made Thanks, leader accelerating strategic with our strong rare and growth our execution in and another XXXX outstanding progress commercial been good quarter we as

for and PBC PFIC medicines portfolio Chenodiol X of PSC across a settings expand As in expanding to inhibition and rare been leverage the LIVMARLI diseases. reminder, in continue our our of goals commercial IBAT medicines, our and adult for have continued growth the this and of drive the year labels strength both CTX

all of We have on this these year. delivered

strong to PFIC of from commercial execution we $XXX all from increasing our quarter, uptake With our and medicines XXXX. continued guidance product with brands continued This quarter trends for net XXXX are million quarter of XX% full the product increase $XXX was increased international third driven in LIVMARLI. very team, commercial the an underlying net across year million, by the million saw the in $XX.X growth third X with Specifically, to sales this strong revenue.

with VANTAGE We has results. PBC the interim breakthrough our pipeline. excellent in designation have based also cholestatic for granted study on pruritus made been progress Volixibat

a for FDA continued Association indicates at least at treatment clinically evidence demonstrate that this Diseases qualify endpoint. accepted have unmet reminder the on As results, preliminary need therapy for substantial PBC in significant American to which clinical the been effects drug over the requires emphasizes strong Study the early designation, This upcoming the of the now abstract existing that designation improvement late-breaking may in a and interim Liver the seen as meeting. one

with in in underway. of Our clinical now remain enrollment settings EXPAND guidance studies and X additional on our Phase PBC is the evaluating and PSC LIVMARLI pruritus cholestatic studies track

genetic we genetic the across Strategically, disorder neurology CTX. male XX,XXX treatment of no program Chenodiol, approved development the pleased CTX to with announce For our for and U.S. addition leading expanded Chenodiol patients date capabilities received to early in and is with affects we've that I'm support building a syndrome also review therapies. that PDUFA share the well are XX. X disability in Fragile priority Fragile candidate December approximately to MRM-XXXX, syndrome. we a aligns the And that rare intellectual of patients the happy with pipeline NDA for I'm a finally, of X with Europe cause with is our of this rare

to go progress call of high-impact for potential in of now I'll ahead Peter Peter? medicines. to the I'm all look industry-leading the to the continue need our will to in expertise disease for leverage over there's rare commercial a clear turn We our patient XXXX where Mirum. proud date opportunities settings and business. over to for

Peter Radovich

I'm with quarter $XX.X total Chris. product net to that sales million. Thanks, of strong say another had we pleased

our pricing sales negotiations through grew $XX.X while and net million. Internationally, in see U.S., million we LIVMARLI distributor has growth million, underway. than In and seeing global in the in are PFIC the come were were headwinds. reimbursement total are With LIVMARLI, despite in to syndrome continue earlier continue to strong from our now contribution growth For in expected. Alagille PFIC third $XX.X product underlying to partners sales sales and from as we see quarter. Alagille solid we international reimbursement pricing demand Europe, U.S. markets both syndrome approved added $XX.X core

CHOLBAM $XX.X to sales product forward our team We steady CTX the for from growth also December. saw date which had business. net quarter, the been commercial tremendous third and looking PDUFA is in in and Chenodiol, it's a Overall, for commercial year continued million of the

PFIC Europe, in We community. price continue patients. portfolio, navigated reach We syndrome effectively to the our LIVMARLI, We to us negotiations grow the to successfully and integrated for bile expanded acid extend our Alagille impact leading label the sales. allowing to we record for

$XXX $XXX continuing forward the execution into over strong it guidance note that, million increased our to year full to million, a ending I'll and look With turn high the we Joanne. Joanne? to of year XXXX. on With

Joanne M. Quan

to quarter productive and Thanks, progress. Peter. pipeline, It our our excited was share for a I'm

for positive improvement I'm be treatment. burden PBC. with to for Volixibat. the Liver will Volixibat. in significant based the PBC as the for with breakthrough therapy and share We're VANTAGE need want breaker late for the AASLD, Volixibat of week. the at on effective an next in progress treated patients designation pruritus decision designation to as patients that a statistically significant was This the data treatment this potential we face placebo happy a making Phase XB presenting showed patients the highlights I pruritus Meeting thrilled analysis interim study, cholestatic versus The highlight First, we're with with which

months. remain track last happy have how the second both half full are and and the the engagement had of XXXX XXXX great by in both For and with groups for PBC. enrollment few PBC We're PSC advocacy to and for PSC on studies investigators over we've programs, with progressing

Moving on to EXPAND.

in potential pruritus. exciting study expansion additional the reminder, LIVMARLI cholestatic for label opportunity an of a represents settings As

started opening excited have sites start We are to screening patients. and

the toward exciting on This for step track PDUFA of Looking for presence year, in in XX end December Chenodiol-CTX. forward genetic our extending is our date an we're the rare neurology.

study X-linked and PDEXD in FXS by this tend affected. opportunity clinic. severely is MRM-XXXX's disability a potential has we be plan study. differentiating, MRM-XXXX different I'm delays. mechanism with intellectual next in and turn to selective our We a is by language It start assets an Fragile brain I'll this or inhibitor, MRM-XXXX. shown to in Next, X X disorder is the concept believe is Fragile males phosphodiesterase We year. updates X its quarter of providing to more males over is penetrant anxiety FXS, thrilled or I'm pleased proof it with evaluate in cause now look Phase also syndrome and across the monogenic the II in forward plan profile and the in the Eric? to to with common syndrome, we of most made and and progress characterized this Fragile future. Eric.

Eric Bjerkholt

the $XX.X summarize. product operating financial flow results I'll in million revenue $XXX.X Earlier trend strengthening issued XX net last our product expenses million, the today, compared were was was expense, quarter million, $XX.X positive which financial briefly cost which Overall, included September $XX.X of million. The performance. and operating and that of of in for quarter ended achieved the $XX for we $X million for included Total of release sales million we total noncash quarter Joanne. compensation year. quarter, million in we cost quarter-over-quarter expense Net third QX, $XX.X excited expense of of continued press Thanks, included a approximately stock-based to $XX.X which and approximately first expense depreciation quarter of time. operating for in amortization cash the XXXX the third to million of third includes sales. R&D revenues that announce the SG&A I'm of

share. loss $X.XX $XX quarter For million XX, was September ended net or the a

of million previous Our cash, investments $X.X $XXX.X quarter. cash XX, the equivalents from million a was as September reduction of and

regulatory The was which fee The deal certain the fiscally with milestones. terms, quarter to cash million grow milestone of advance we hand. subject and upon a of summary, development are disciplined. the million, European continue to in on we approval payment we quarter independent start and MRM-XXXX to and fourth will a and pay third sales-based upfront cash million enhance $XX drug Phase the remaining Takeda pipeline, indication. $X.X business financially commercial Under III and PFIC all the used for $X.X while included our milestone In LIVMARLI the

to the I'll for Chris over call turn final Now comments. back

Christopher Peetz

Thanks, great quarter Eric. for It a been Mirum. has

resulting guidance. performing well are increased Our year commercial with growth full from strong programs

with Mirum recent next strong study breakthrough volixibat's call LIVMARLI the up with And the all please II planned a questions. for initiation start financial Phase to driven that, with team added has open Our and finish with operator, and pipeline delivering for the And the of a us is discipline, this setting MRM-XXXX of designation year. EXPAND the year. for

Operator

Gavin from ISI. Evercore [Operator Instructions] Clark-Gartner First question is from

Gavin Clark-Gartner

Congrats on all the progress.

just in So to Fragile focus wanted I on X.

the clinical endpoints? X? pursue just So endpoint familiar, or accelerated in less Is to current an cognitive first those any maybe registrational who And path? there here, on question Fragile what's are it for behavioral opportunity is

Christopher Peetz

Joanne to on strategy actually endpoints. over our the Gavin, to I'll thinking for thanks question. turn it talk and about

Joanne M. Quan

thanks Yes. the for Gavin, question.

think history, for for the is We no field. NIH other a use path we a been toolbox forward. studies used, acquired we've the the really you have registrational the a positive discussions we but have been and And endpoint. very if that's past, FDA, as think I thinking the problematic at just look with haven't that Our endpoints which we in [indiscernible], is also further had also this different program, than been is can inhibitor. that Obviously, viable there recognize PDX so the do

brain molecule, our advantages with and there's penetration some the the actually However, in really selectivity forward. provides high that developing we think

of terms forward in excited forward and moving FDA. really that we're the there's So think viable path do with a this

Christopher Peetz

to the is programs excited Mirum, And us have with what our this here and that one toolbox program experience the NIH on at comment gets clinical patient we just of endpoint. about This outcomes on part the of add and the test the leaning conducted -- to plan. on patient-reported is similar what and all that

Gavin Clark-Gartner

with II? to regulators helpful. planning That's likely the Phase II to will Got you engagement any Phase it. Or are prior of be have end next initiating engagement And meeting?

Joanne M. Quan

the for Gavin, Thanks, Yes. follow-up.

the be engaging with FDA early on this program. year We next will

Operator

Jessica Fye Our next from is at question JPMorgan.

Jessica Fye

That's present? interim? data would had this you I -- expect volixibat, the a will subgroups, of focus AASLD share more from little first, on will from much What should what presentation VANTAGE the be? detail we if on? And the any, the at one. you late-breaking an on How couple a you can update street

LIVMARLI, looks Second, really quarter-over-quarter, growth was it year-over-year. like solid

think you this the of then in-licensing, year, you seasonal last development Did about XQ, see context you headwinds. lastly, latest see year? how on of do evolving talked And on of I remain this in rare kind legacy any do company on with going the that beyond kind back liver the this of asset BD this kind you focus? in-licensing? disease And of of to kind expect the of active the business front

Christopher Peetz

volixibat days late for on being BD the away breaker, trends. a comment just Jess, for I'll the question. speak Thanks, commercial handful to Peter and released. the of these volixibat On strategy touch let the quick from on and we're

out seen kind there, on that we've focus, the update with just That the towards we're Real So data is the already there. point pursuing. strong endpoint coming and response pruritus. is soon registrational really line top right, just that of is you

XXXX very BD in and the take a to -- see to think excited still we as as strategy, I early-stage and to share step On the update. addition program, this back put just data excited So do steps this that about an the on we've a at add that lot focused are of and overlooked rare team with now programs of pursuing years disease, genetic that's for disease a can particular, one several value. Mirum that been here been rare

the at really I'll I on of on with comment thoughtful great how between that, well And our last a get year, in bookend outcomes. the side, last it is as example and this approach diseases example transaction the look products. of of where program So terms fits of the is bringing XXXX of development diagnosed as capabilities patient-reported commercial see and a to endpoints we genetic things treated kind a make that

time as for this earlier of where And Peter end of with pass see it commercial our we of the spectrum over on terms in strategy. to You the I'll maybe focus kind the BD side. that,

Peter Radovich

of a in With regards has LIVMARLI all in something comment Yes. in as the It we a really not Jess, XXXX. some observed on at slowdown did the we you months been summer to bit LIVMARLI. trends, mentioned, of XXXX, with

quarter Alagille syndrome in international. we've of of from growth as line launch kind as well really been with syndrome a in This kind performance solid continued with U.S. growth the strong strong in Alagille what and was seeing PFIC in

Operator

is next Our from question Foroohar Mani Leerink Partners. from

Unknown Analyst

starts Mani. moving on royalties should what where switches and this few on forward? means is And it You Congrats just color the this quarter. any you share from? then XXXX. the as specifics we whether specifically And expect one that any patient just acceleration a moving or for or provide is line, Can PFIC guess the coming you growth milestones seeing commercial that negligible? on program? be OpEx do the forward? for Brian in impact have such you front. a for competitor terms on future pretty Or OpEx from on I then more So on deal new Can to expect that you're program around this

Christopher Peetz

Great. pass I'll off the Eric to questions. for both Peter touch Brent, thanks on it question. to and

Eric Bjerkholt

Yes. Thanks.

provide comments through. went the financial I we my commentary some that So terms just on in did

pre-regulatory million was and sort milestone. $X.X only Phase III million is upfront $X.X the the milestone stock the approval So really of

on, we're to royalties, but stage. very Our of comment not this for typical a deal going they're

modest. pretty So

just to terms our side we're spend, of plans early But could percentage terms of specific sense on clinical think in too a in the it as to you of well increase both in the of this because about asset, it's in R&D the manufacturing our as be sort you of percentage-wise. spend, mid-teens In being for side. give early the terms developing too rough

Christopher Peetz

targeted we of bringing into just this Yes. at And concept. quite early-stage see it proof efficient as perspective how in is to get much program put to to kind that program an of that very looked investment of Mirum,

in design from amount not a spent. the really Phase investment of dollars deal big into terms the II and terms to that step So spend, clinical the the of

Peter Radovich

Brian, yes, what's the And to PFIC question your driving on performance.

reimbursement. I think an is really comment overarching

did rare usually our other come for slower based online. as would disease more access as than a we of Our kind on new-to-market policies and might few coverage market a Alagille reimbursement where team you approvals of quarters anticipate approval to job great well sooner expect PFIC securing reimbursement even be when

we than So that came faster online thought.

trial de our being talked rolled XXs as of that patients low seeing about In the in demand, and about well. in be sources launch. IBAT demand. of switches past those of terms then we've U.S. we in are are naive, the the were expanded clinical to Probably the seeing And some access majority novo rollover are ready over after we

Operator

Dae Our from Ha next Gon is from question Stifel.

Dae Gon Ha

pretty well. ahead. I Congrats questions as on looking me bright guess couple the a quarter, of from

I Just thinking the or guess, growth about but not OpEx guidance the increase. revenue OpEx,

But we Or we modeling is about purposes? When think primarily is PFIC it expand sites about in if line going that about envision kind of that Joanne, enrollment in QX? can cadence more? be you be and to any a ahead the lastly, are on as great. bit curious completion, Alagille you of terms of Just outlook then opening. it little time You And patient driven would think on by MRM-XXXX. growth terms in said really enrollment EXPAND, of

here. But inhibition Fragile anything on Fragile Is the are after point is starting about the the expanding curious Just for strategy thinking that's overall neurology mean, indications? side. PDEX X your X? lower-hanging on I about fruit there you other

Christopher Peetz

from for the Maybe, you start there? question. EXPAND the with to Joanne, question Thanks want

Joanne M. Quan

Yes. question. Thanks for the

we're study where EXPAND, start. of on terms are, of right track of terms we In the terms in in

shortly. up have we expect to sites and we start and screening running, So

enrollment from terms has in before. line changed time not guidance of Our

to XX expect months so [indiscernible] or then there. from we and roughly So

track. So that's really on right

Dae Gon Ha

And then on the sales trends?

Peter Radovich

Yes, Dan.

drives we guidance yes, $XXX million what So that. to obviously in $XXX raised million, our terms of

We is QX by in with and saw in yes, growth in in see the line kind that coming Alagille continue in in guidance trends. launch the the QX really PFIC of to we forward strong the U.S. historical of is our U.S. that uptick driven kind And

Christopher Peetz

potential broader opportunity way may before of II get kind other it. of putting in in focused we against touch There just indications, proof dollars this Phase kind first a be to the PDEXD. for we're concept but very approaching Fragile X in program of And to broader on the in consider to

forward really So and for first looking to generating proof-of-concept that data Fragile from and what can X mean patients, that go there. we'll

Operator

Baird. The next from at Brian is question Skorney

Brian Skorney

in Phase with I X. PDEXD, a run know Xanthomas the On III Shionogi is Fragile

the And I'm with and just molecule the you with the of compare can contrast then Shionogi and that before you maybe of the of licensing Phase II year? so powering? next would initiating potential Phase endpoints that is kind on maybe those basis II on wait wondering, results here? readout the deal sort your you anticipate decide study And would data And to one? of Or

Christopher Peetz

that what it differentiated into independent, But as stronger speak Brian. Yes. question, a are monitoring obviously the these I'll I'll that But results from differentiation Phase that to we program, interesting. see. The terms how let we did let program. II the [indiscernible]. somewhat what first, are think, the data of comes little I in program. liked of at Joanne quite that the than given That looked could to this though out the I weigh we Thanks profile, start about pipeline. for some proof-of-concept study of see of into we we to think see timing, Joanne program bring bit speak

Joanne M. Quan

plasma cyclic to cGMP is Yes. is we're I the Brian, do alter to one we high just the within selective. trying molecule the brain. The brain what from levels points thanks think highly of differentiation ratio key other And simply the because molecule for the have the question. is

molecule advantages here. has that potential think we our some so And

point. MRM-XXXX mind [indiscernible]. obviously, keep that's differentiation potential And look We're applications program. the results other at about a I key that we'll as So for think excited the we for and in potential [indiscernible]

Operator

question Lebowitz The is from next David from Citi.

David Lebowitz

the relative are you going Can your strategy to in assets development the about forward? decisions Travere what with in-license thinking you general XXXX business compare to and

Christopher Peetz

volixibat active Thanks, I and the to looking how that can expertise frankly, products. outcomes, on David. expand over is looked acquiring and think really the that transaction some the the experience disease founding of But Phase the put spectrum overlooked a where bit value of you our the and I team these came spaces driven, X in kind deep looking rare give about that. to I/Phase color, for LIVMARLI turn and little have perspective in Mirum both disease, active can on. use grow of types can -- of has really at talk to at from And actually I way it are rare where the that of transactions we're Peter is team things particular, to II ready of some a Mirum commercial patient-reported I'll of transactions lot genetically we're and and in with search these looking settings of we've

side, us build the so the side, the to on the clinical gives future ability And into on to commercial ability performance, us drive growth the gives company. financial and

of to transactions together Mirum. I'll those build quite to see about the Peter really we So to at. it look different talk what turn over working of well kind profile out

Peter Radovich

it's great you a -- mean I I Yes. question. think can

for to in patients, significant being The these by X to professionals, for pediatric transaction care products with underappreciated the these we've the insight acid bile that the may transactions. having a led us point interestingly, in of space, one neurologists. record hands, grow think be most the happy that You prescribers highs. knowing our and and create health I with our products liver over what and And way caregivers, of at value Travere can in these about to of performance had look year came Chenodiol, there, continuing are is we're

sort and neuro for what the replacement cetera, underappreciated et acid a into And this even really, of last where neurologic, gotten bile this we've of kind of XXXX. of in that's conferences, been kind field, us though gained we year, insight medical manifestations and may the it's field product, and another over so are the be program kind in

programs. one theme and underappreciated think rare high I So for is patients disease just impact

Operator

Steve James The Raymond next Financial. at comes from question Seedhouse

Timur Ivannikov

This is Congrats on Steve Seedhouse. Timur on quarter. the Ivannikov for

about questions have We X. couple a Fragile of

activity old? those xanthomas plans So one first enroll normal? on molecule leaving versus have of in And to achieve the you much is what the you patients specifics, than at is then brain? the enroll much point how the And do know in CM can do you is, you table years could That patients? how younger terms XX more

Christopher Peetz

I'll and of Joanne some start on here. Yes. details, the the I let appreciate finish but question

we're to update X to with year interact with planning initial the going -- Phase do of input. finalize to are propose. next on some have we'll FDA regulatory with but early We some it elements, thinking Caveat that what

Joanne M. Quan

for Thanks Yes. question. the

of In in kinds we and Phase step included age terms the range, these Currently, program, then programs well. will volunteers adult of to which try basic elderly number the patients age. to start And of large fairly from it's that's prior healthy have as the and approach have we in patients. a down that information typical X with adult

use most for that patients around Fragile with age X. going think be helpful we'll age particularly so are X then step And diagnosed down and will because Fragile down that age. And in in strategy X we

be something this for for children will disease. impactful So having particularly

brain-to-plasma In terms We is higher our pretty how kind of the nervous know a bit actually activity, system quite central ratio of do more gauge. that to that's a much xanthomas. thing than difficult

differentiating for that, pudding compounds we the other any feature the of big compared will are that that Obviously, terms advantages to in an but looking that think XXXX this in results, confident at the of is we're us here. some So pretty in will be important the clinic. proof give

Operator

at Morgan is Stanley. Mike question next from The Ulz

Michael Ulz

might market December. now one that on sort CTX you and late on have opportunity label have Maybe impact in of and PDUFA getting the date just potential remind what what the is just sales? that a Maybe chenodiol us there

Peter Radovich

Yes. question, the for Thanks Mike.

promotion. about and the So potential be with to really we're opportunity active there approval excited out really, the

emergency a and chenodiol a of suggest on with Just for this about diagnosed. to under a We maybe with best XX% only literature it those under approved while patients estimates have the different about there's chance active prevalent reminder, CTX, X,XXX promotion. think to X,XXX is and here available use U.S. indication label in be the will

So of on our increase a try awareness approval a then trajectory lot our And a effort it little to extent can and state be I reflected increase to current will the diagnosis even in bit, you sales promotion disease we upon have numbers meaningful that rate. impact see the ultimately, today. think it could on

Operator

from question next The comes John JMP. from Wolleben

Unknown Analyst

is just for to have and then updates expansion on And kind seeing launch, question if LIVMARLI, any what comment you This a just of your Catherine been? PFIC views on given could you're for ex-U.S. quarter how the strong the about on John. quick global I that. has

Christopher Peetz

pull But and overall, Thanks is reimbursement. initial this of of early for days make seeing I'd really one PFIC just demand. the comment good Yes, on questions, Catherine. this forward some was the

that's -- earlier really I'll as some the Peter international So stronger quarter step-up this we than because a let aspects. being of of reimbursement. that But speak others to do see

Peter Radovich

in several Yes. Yes, midsized have in plus Alagille and reimbursement pricing we've I major EU four the now absolutely. mean markets approval markets.

around the there of that patients potentially and has proud continue team delivered distributor find the syndrome more LIVMARLI. benefit really So Alagille partners world we with to our execution could

international to And well. the recently. Europe and markets came in approval launch go So PFIC continues the Alagille yes,

maybe international as next now, and you move obviously into mid half on. reflected of with the coming of to in that not So reimbursement half back pricing sales next year back year, is

Operator

next H.C. The from question Wainwright. from comes Ed Arce

Wing Yip

a This questions asking couple for Ed. Yip of is Thomas

give on following suppose on EU? us so discussions for Can percentage PFIC first have prescribers reached U.S. So the payer target previous in what and you details perhaps you I far? question, more question. the specifically, of

Peter Radovich

the really beauty frankly. maybe market a the quite Alagille are is every as subset those, the and syndrome we're in active mean same even of I Yes. PFIC of prescribers in

PFIC demand reached days of as numbers. in seen we've we QX I the and and we and reaching can where think point, majority at vast I but and in we this reaching seeing into individual are. the Europe, have places as move think in the our interest be you're where I PFIC as Germany countries, we'll them in -- conversations PFIC the sales about reimbursement substantially providers launch more Early the certainly as great comes U.S. of all So of launch nice profile closer think next and quickly, pricing and year to

Wing Yip

perhaps question then And another LIVMARLI. for

if wondering for the have enrollment EXPAND far? you feedback can so investigator initial perhaps discuss or any Just you that progress study

Christopher Peetz

that can briefly Thanks, just the for question. just mean I touch I being that Thomas, on are in sites now opened.

So we patients. starting open have and to sites screen

investigator use to I for for that within of the on patients to of -- initial idea too early looking remind are interest access kind interest get So and that study. comment protocol that whole you there. But the the and the really the study compassionate and progress will study design fit the came from prescriber

So it that's the demand to to add patient an this indication driven by and is physician label. LIVMARLI

place. lot a in us of that first So that together study still the put the to same led see dynamic

Wing Yip

more from one question Perhaps Understood. us.

with a does disorder rare just XXXX, mean lucatinib of for diseases genetic that in target the general? is now in-licensing or So Mirum

Christopher Peetz

Yes. have overall, these the and commonality Thanks thoughtful are on active the the of as for change across all side, of team And settings. there. endpoints, areas different of plays with commercialized different conditions, you and therapeutic all disease commercial approach need for. in these diagnosed the a see it number genetic question of we're itself mean, that a I And because on that and we patients how area therapeutic doesn't what are somewhat rare looking prescribers.

in build see number as across see and do of them both to shown we some clinically that different we a settings, can opportunity opportunities we while these because outside there's add value So of we've well of commercially. subspecialties

Operator

hand I'll back now the call conclude Q&A concludes to Peetz, CEO, This to the call. Chris session. the

Christopher Peetz

Great. everyone, great Thanks, Goodbye. have for joining today, a and day. us

Operator

today's Call. Thank for XXXX you Pharmaceuticals Mirum Third Results all Quarter joining

disconnect. now may You

Mirum Pharmaceuticals (MIRM) 12 Nov 242024 Q3 Earnings call transcript